MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company focused on creating innovative oral therapies for neurologic and neuropsychiatric disorders. Their lead candidate, Ketamir-2, is a patent-pending oral ketamine analog under investigation for treating neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. Additionally, MIRA is developing MIRA-55, an oral pharmaceutical marijuana analog aimed at addressing anxiety and cognitive decline associated with early-stage dementia. Both compounds have been reviewed by the U.S. Drug Enforcement Administration and are not considered controlled substances, facilitating their development and potential future commercialization.